Trends in stereotactic body radiation therapy for stage I small cell lung cancer
Trends in stereotactic body radiation therapy for stage I small cell lung cancer
复制标题
DOI：
10.1016/j.lungcan.2016.11.009
复制
发表时间：
2017-01-01
期刊：
影响因子：
5.3
通讯作者：
Decker, Roy H.
中科院分区：
文献类型：
--
作者：
Stahl, John M.;Corso, Christopher D.;Decker, Roy H.
目的：我们的目的是报告的趋势，立体定向体部放射治疗（SBRT）的利用，剂量处方，化疗管理I期小细胞肺癌（SCLC）在UnitedStates.Materials和方法：国家癌症数据库（NCDB）被用来确定患者cT 1 -2 NO小细胞肺癌治疗SBRT在2004年和2013年之间。分析了SBRT使用和剂量处方随时间的趋势。采用多变量logistic回归分析确定与SBRT化疗相关的因素。Kaplan-Meier法被用来估计总survival.Results：9265例临床I期SCLC患者进行了初步治疗分配检查，285例接受SBRT治疗，并代表了主要分析的主题。SBRT的使用率从2004年（占当年诊断的所有I期患者的0.4%）增加到2013年（6.4%）。在同一时期，明确的手术治疗也从2004年的14.9%增加到2013年的28.5%。SBRT生物有效剂量（BED 10）中位数为112.5戈伊（范围：72-290），285例患者中仅33例（11.6%）接受了BED 10
Objectives: We aimed to report trends in stereotactic body radiation therapy (SBRT) utilization, dose prescriptions, and chemotherapy administration for stage I small cell lung cancer (SCLC) in the United States.Materials and methods: The National Cancer Data Base (NCDB) was used to identify patients with cT1-2 NO SCLC treated with SBRT between 2004 and 2013. Trends in SBRT use and dose prescription were analyzed over time. Multivariable logistic regression was used to determine factors associated with the administration of chemotherapy with SBRT. The Kaplan-Meier method was used to estimate overall survival.Results: Of 9265 patients with clinical stage I SCLC who were examined for initial treatment allocation, 285 were treated with SBRT and represented the subject of the primary analysis. SBRT utilization increased from 2004 (0.4% of all stage I patients diagnosed that year) to 2013 (6.4%). During this same time period, definitive surgical management also increased from 14.9% of all patients in 2004 to 28.5% in 2013. The median SBRT biologically effective dose (BED10) was 112.5 Gy (range, 72-290) and only 33 out of 285 (11.6%) received a BED10